Postherpetic Neuralgia

Cross-source consensus on Postherpetic Neuralgia from 1 sources and 6 claims.

1 sources · 6 claims

How it works

Risks & contraindications

Comparisons

Other

Highlighted claims

Between 5% and 30% of individuals who develop herpes zoster subsequently develop PHN. — Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis
Annual expenditure attributable to herpes zoster and PHN complications reaches billions of US dollars globally, encompassing direct medical costs and productivity losses. — Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis
The incidence and prevalence of PHN vary markedly across geographic regions and demographic groups, driven by ageing demographics, regional disparities in vaccination coverage, differences in healthcare access, and genetic susceptibility. — Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis
Postherpetic neuralgia is defined as pain persisting more than 90 days after herpes zoster rash onset. — Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis
PHN pain can manifest as shooting, burning, sharp, stabbing, or electric shock-like sensations and may persist for months to years. — Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis
PHN severely impairs psychosocial function, disrupts sleep, daily activities, and work capacity, and causes significant psychological distress and increased healthcare utilisation. — Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis